Menglin Zou1, Jianjun Xie2, Lili Lan3, Yiye Zhang3, Liqing Tian3, Man Chen3, Yan Yan4. 1. Department of Nephrology, Gaoxin Branch of the First Affiliated Hospital of Nanchang University, Nanchang City, Jiangxi Province, China. 2. Hospital of Jiangxi Provincial Armed Police Corps, Nanchang, People's Republic of China. 3. Department of Nephrology, The First Affiliated Hospital of Nanchang University, No. 17 Yongwai Avenue, Nanchang City, Jiangxi Province, China. 4. Department of Nephrology, The First Affiliated Hospital of Nanchang University, No. 17 Yongwai Avenue, Nanchang City, Jiangxi Province, China. kiddoc@163.com.
Abstract
BACKGROUND: Present investigation aims to elucidate safety and efficacy of hemodialysis as well as peritoneal dialysis in treating end-stage diabetic nephropathy. METHODS: We searched various databases for articles from the database starting date to October 2019. The analysis involved studies that contained outcomes of hemodialysis and peritoneal dialysis in the treatment of end-stage diabetic nephropathy. A total of 12 randomized controlled trials (RCTs) with 932 participants were collected. RESULTS: Meta-analysis results suggested that comparing with peritoneal dialysis group, hemodialysis group had a higher incidence of cardiovascular and cerebrovascular events and bleeding complications. There was no statistically significant difference regarding the infection (P = 0.71) or malnutrition (P = 0.53) incidence between the two forms of dialysis. Hemodialysis could better improve the levels of albumin [mean difference (MD) = 6.80, 95% CI = (4.17-9.44)] and hemoglobin [MD = 3.40, 95% CI = (0.94-5.86)] than peritoneal dialysis after 3 months or more. CONCLUSIONS: In treating end-stage diabetic nephropathy patients, peritoneal dialysis had a lower incidence of cardiovascular and cerebrovascular events, as well as bleeding complication than hemodialysis. However, hemodialysis could better improve albumin and hemoglobin levels than peritoneal dialysis after 3 months.
BACKGROUND: Present investigation aims to elucidate safety and efficacy of hemodialysis as well as peritoneal dialysis in treating end-stage diabetic nephropathy. METHODS: We searched various databases for articles from the database starting date to October 2019. The analysis involved studies that contained outcomes of hemodialysis and peritoneal dialysis in the treatment of end-stage diabetic nephropathy. A total of 12 randomized controlled trials (RCTs) with 932 participants were collected. RESULTS: Meta-analysis results suggested that comparing with peritoneal dialysis group, hemodialysis group had a higher incidence of cardiovascular and cerebrovascular events and bleeding complications. There was no statistically significant difference regarding the infection (P = 0.71) or malnutrition (P = 0.53) incidence between the two forms of dialysis. Hemodialysis could better improve the levels of albumin [mean difference (MD) = 6.80, 95% CI = (4.17-9.44)] and hemoglobin [MD = 3.40, 95% CI = (0.94-5.86)] than peritoneal dialysis after 3 months or more. CONCLUSIONS: In treating end-stage diabetic nephropathy patients, peritoneal dialysis had a lower incidence of cardiovascular and cerebrovascular events, as well as bleeding complication than hemodialysis. However, hemodialysis could better improve albumin and hemoglobin levels than peritoneal dialysis after 3 months.
Authors: Yan Yan; Dan Ye; Liu Yang; Wen Ye; Dandan Zhan; Li Zhang; Jun Xiao; Yan Zeng; Qinkai Chen Journal: Ren Fail Date: 2018-11 Impact factor: 2.606